Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Response to therapy among patients with acute exacerbation of chronic Hep C

The latest issue of Clinical Gastroenterology & Hepatology investigates clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic Hepatitis C.

News image

The slow asymptomatic progression of chronic hepatitis C can be interrupted by an acute exacerbation, characterized by increased serum levels of alanine aminotransferase and bilirubin and other symptoms of acute hepatitis.

Dr Evangelista Sagnelli and colleagues provided more information about the clinical presentation of acute exacerbation of chronic hepatitis C.

The research team identified 82 consecutive patients, from 2 locations in Italy, who had an acute exacerbation of chronic hepatitis C from 2005 through 2010.

The team followed them up for a median period of 36 months.

Hepatitis C virus genotype 2 was detected in 46% of cases
Clinical Gastroenterology and Hepatology

These cases were hepatitis C virus RNA positive, hepatitis B surface antigen-negative, and had not received anti-hepatitis C virus therapy.

The cases were matched with 82 subjects with hepatitis C without reactivation for age, sex, and hepatitis C virus genotype.

The researchers followed 69 cases, and 73 controls were followed up for at least 2 years.

Liver biopsy specimens had been taken from 23 cases and 31 controls—once before enrollment in the study and once during the follow-up period.

The research team detected hepatitis C virus genotype 2 in 46% of cases, and hepatitis C virus genotype 1 was detected in 44%.

Among cases, the mean alanine aminotransferase level was 1063 IU/dL, and the mean total bilirubin level was 16 mg/dL.

The doctors analyzed a higher percentage of cases carried the interleukin-28B CC genotype than controls.

Among cases, 44% had a steady increase in alanine aminotransferase level for 56% of these patients, alanine aminotransferase levels returned to baseline values before the acute exacerbation of chronic hepatitis.

Based on comparisons of biopsy specimens, 18 cases and 11 controls had increasing fibrosis, with Ishak scores increasing by more than 2.

The team found that 14 cases and 3 controls had increases in necroinflammation of more than 2 points.

The researchers observed that 32 cases and 38 controls received treatment with pegylated interferon and ribavirin.

A sustained virologic response was achieved in 26 cases and 23 controls.

Dr Sagnelli's team commented, "Although an acute exacerbation of chronic hepatitis is a serious medical condition, most patients achieve a sustained virologic response after treatment with pegylated interferon and ribavirin."

Clin Gastroenterol and Hepatol 2013: 11(9): 1174-1180
19 September 2013

Go to top of page Email this page Email this page to a colleague

 26 April 2015

Advanced search
 24 April 2015 
GastroHep.com Easter break
 23 April 2015 
Gut microbiota modulation for alcoholic liver disease
 23 April 2015 
Moderate sodium restriction diet in cirrhosis
 23 April 2015 
Gastroesophageal junction disruption and obesity
 22 April 2015 
Hepatitis and mortality in hospitalized patients
 22 April 2015 
Magnetic sphincter augmentation for GERD
 22 April 2015 
Drug, herbal and dietary supplement hepatotoxicity
 21 April 2015 
Risk factors of postpartum bowel changes
 21 April 2015 
Tracking colonoscopy surveillance intervals
 21 April 2015 
PPI increases risk of cryptogenic liver abscess
 20 April 2015 
IBS after traveller's diarhea
 20 April 2015 
Economic impact of C. diff infection
 20 April 2015 
Adherence to Hep C treatments
 17 April 2015 
Synchronous colorectal advanced neoplasia
 17 April 2015 
PNPLA3 polymorphisms and NAFLD risk
 17 April 2015 
MELD score and colorectal resection
 16 April 2015 
Bleeding risk in colonic diverticulosis
 16 April 2015 
Minority use of high-volume hospitals for colorectal cancer
 16 April 2015 
Sleep and IBD
 15 April 2015 
Treatment of hepatocellular carcinoma
 15 April 2015 
Score predicts malignant bile duct obstruction
 15 April 2015 
Increased risk of Barrett esophagus
 14 April 2015 
Improving colorectal cancer screening uptake
 14 April 2015 
Colorectal cancer presenting under the age of 50
 14 April 2015 
Functional constipation vs constipation predominant IBS
 13 April 2015 
Fecal transplant for C. difficile
 13 April 2015 
Immune based treatments for HCC
 13 April 2015 
CRP and acute diverticulitis
 10 April 2015 
Hypnotherapy for IBS
 10 April 2015 
Adjuvant therapy after rectal cancer
 10 April 2015 
Viral outcomes in HCV infection
 09 April 2015 
Male IBD patients wishing to conceive
 09 April 2015 
Screening programs based on the fecal immunochemical test
 09 April 2015 
Management of esophageal food impaction
 08 April 2015 
Nonceliac gluten sensitivity
 08 April 2015 
Ambulatory hemorrhoidal surgery
 08 April 2015 
Iron fortification and gut inflammation
 07 April 2015 
Endoscopic managements of GI bleeds
 07 April 2015 
Interventions for eosinophilic esophagitis
 07 April 2015 
Treatment of Hep C virus
 06 April 2015 
Treatment for rectal cancer
 06 April 2015 
Risk stratifying Barrett's esophagus
 06 April 2015 
Cost-effectiveness of HCV
 03 April 2015 
Predicting advanced cancer in Barrett's
 03 April 2015 
Vitamin D deficiency and Hep B outcomes
 03 April 2015 
Hepatocellular carcinoma surveillance in cirrhosis
 02 April 2015 
Physical activity and NAFLD
 02 April 2015 
Genetic risk for Crohn's disease
 02 April 2015 
EUS for detection of pancreatic neuroendocrine tumors
 01 April 2015 
Analysis of liver fibrosis
 01 April 2015 
Obeticholic acid in primary biliary cirrhosis
 01 April 2015 
Mortality rates for upper GI bleeds
 31 March 2015 
HCV-HIV co-infection combination therapy
 31 March 2015 
Placement of nasoenteral feeding tubes
 31 March 2015 
Hepatic fat and gallbladder polyps
 30 March 2015 
Minimally invasive approach in colorectal procedures
 30 March 2015 
Prevalence of IBD in USA residents of Indian ancestry
 30 March 2015 
Treatment of pediatric IBD
 27 March 2015 
Screening for fecal incontinence
 27 March 2015 
Deep remission in Crohn's disease

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us